Shots:

• The NIH discontinues an enrolment in the P-III (ACTIV-2) trial of SAB-185 in patients with COVID-19 at higher risk for progression to hospitalization
• The discontinuation is due to a reduction in low Omicron-related COVID-19 hospitalization & death rates while the therapy has previously met the pre-specified safety & efficacy criteria & the study can be stopped for reasons of operational futility, following the recommendation of DSMB
• The company is planning for future programs of SAB-185 including targeted applications. SAB-185 is a targeted, highly potent, fully human polyclonal Abs & demonstrated neutralization of multiple SARS-CoV-2 variants in vitro, including Delta and Omicron

Ref: Globe Newswire | Image: Globe Newswire